Skip to main content
Top
Published in: Calcified Tissue International 6/2007

01-12-2007

Three Novel Mutations of the PHEX Gene in Three Chinese Families with X-linked Dominant Hypophosphatemic Rickets

Authors: Weibo Xia, Xunwu Meng, Yan Jiang, Mei Li, Xiaoping Xing, Li Pang, Ou Wang, Yu Pei, Li-Yun Yu, Yue Sun, Yingying Hu, Xueying Zhou

Published in: Calcified Tissue International | Issue 6/2007

Login to get access

Abstract

X-linked dominant hypophosphatemia (XLH, OMIM307800), the most prevalent form of inherited rickets in humans, is a dominant disorder of phosphate homeostasis characterized by growth retardation, rachitic and osteomalacic bone disease, hypophosphatemia, and renal phosphate wasting. The gene responsible for XLH was identified by positional cloning and designated PHEX (formerly PEX) to depict a phosphate-regulating gene homologous with endopeptidases on the X chromosome. Recently, extensive mutation analysis of the PHEX gene has revealed a wide variety of gene defects in XLH. The ethnic distribution of the mutations is very widespread but only a few mutations in Chinese have been reported. To analyze the molecular basis in three unrelated Chinese families with XLH, we determined the nucleotide sequence of the PHEX gene and fibroblast growth factor 23 (FGF23) gene of affected members. The serum FGF23 concentrations of these patients with XLH were also measured. Three different novel mutations were observed in these three families: one deletion mutation c.264delG causing p.W88 X; one missense mutation c.1673C>G causing p.P558A; one nonsense mutation c.1809G>A causing p.W603 X. Serum concentration of FGF23 in XLH patients of these three families was significantly higher than normal. The results suggest that PHEX gene mutations were responsible for XLH in these patients and these mutations may contribute to a higher serum FGF23 level.
Literature
1.
go back to reference Rasmussen H, Tenenhouse HS (1995) Mendelian hypophosphatemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Basis of Inherited Disease, vol 2. McGraw Hill, New York, pp 3717–3745 Rasmussen H, Tenenhouse HS (1995) Mendelian hypophosphatemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Basis of Inherited Disease, vol 2. McGraw Hill, New York, pp 3717–3745
2.
go back to reference Whyte MP, Schranck FW, Armamento R (1996) X-linked hypophosphataemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. J Clin Endocrinol Metab 81:4075–4080PubMedCrossRef Whyte MP, Schranck FW, Armamento R (1996) X-linked hypophosphataemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. J Clin Endocrinol Metab 81:4075–4080PubMedCrossRef
3.
go back to reference Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphataemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate wasting disorders. J Clin Endocrinol Metab 82:674–681PubMedCrossRef Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphataemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate wasting disorders. J Clin Endocrinol Metab 82:674–681PubMedCrossRef
4.
go back to reference Rowe PS (1994) Molecular biology of hypophosphataemic rickets and oncogenic osteomalacia. Hum Genet 94:457–467PubMedCrossRef Rowe PS (1994) Molecular biology of hypophosphataemic rickets and oncogenic osteomalacia. Hum Genet 94:457–467PubMedCrossRef
5.
go back to reference HYP Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130–136 HYP Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130–136
6.
go back to reference Rowe PS, Goulding JN, Francis F, Oudet C, Econs MJ, Hanauer A, Lehrach H, Read AP, Mountford RC, Summerfield T, Weissenbach J, Fraser W, Drezner MK, Davies KE, O’Riordan JL (1996) The gene for X-linked hypophosphataemic rickets maps to a 200–300 kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE). Hum Genet 97:345–352PubMed Rowe PS, Goulding JN, Francis F, Oudet C, Econs MJ, Hanauer A, Lehrach H, Read AP, Mountford RC, Summerfield T, Weissenbach J, Fraser W, Drezner MK, Davies KE, O’Riordan JL (1996) The gene for X-linked hypophosphataemic rickets maps to a 200–300 kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE). Hum Genet 97:345–352PubMed
7.
go back to reference Holm IA, Huang X, Kunkel LM (1997) Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet 60:790–797PubMed Holm IA, Huang X, Kunkel LM (1997) Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet 60:790–797PubMed
8.
go back to reference Du L, Desbarats M, Viel J, Glorieux FH, Cawthorn C, Ecarot B (1996) cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics 36:22–28PubMedCrossRef Du L, Desbarats M, Viel J, Glorieux FH, Cawthorn C, Ecarot B (1996) cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics 36:22–28PubMedCrossRef
9.
go back to reference Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663PubMedCrossRef Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663PubMedCrossRef
10.
go back to reference Weber T, Liu S, Indridason O, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner Res 18:1227–1234PubMedCrossRef Weber T, Liu S, Indridason O, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner Res 18:1227–1234PubMedCrossRef
11.
go back to reference Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC (2001) FGF23 inhibits renal tubular phosphate transport and is a phex substrate. Biochem Biophys Res Commun 284(4):977-981PubMedCrossRef Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC (2001) FGF23 inhibits renal tubular phosphate transport and is a phex substrate. Biochem Biophys Res Commun 284(4):977-981PubMedCrossRef
12.
go back to reference Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419–37426PubMedCrossRef Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419–37426PubMedCrossRef
13.
go back to reference Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD (2006) Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291:E38–E49PubMedCrossRef Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD (2006) Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291:E38–E49PubMedCrossRef
14.
go back to reference Rowe PS, Oudet CL, Francis F, Sinding C, Pannetier S, Econs MJ, Strom TM, Meitinger T, Garabedian M, David A, Macher MA, Questiaux E, Popowska E, Pronicka E, Read AP, Mokrzycki A, Glorieux FH, Drezner MK, Hanauer A, Lehrach H, Goulding JN, O’Riordan JL (1997) Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet 6:539–549PubMedCrossRef Rowe PS, Oudet CL, Francis F, Sinding C, Pannetier S, Econs MJ, Strom TM, Meitinger T, Garabedian M, David A, Macher MA, Questiaux E, Popowska E, Pronicka E, Read AP, Mokrzycki A, Glorieux FH, Drezner MK, Hanauer A, Lehrach H, Goulding JN, O’Riordan JL (1997) Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet 6:539–549PubMedCrossRef
15.
go back to reference Jan de Beur SM, Levine MA (2002) Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metab 87:2467–2473CrossRef Jan de Beur SM, Levine MA (2002) Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metab 87:2467–2473CrossRef
16.
go back to reference Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y (2005) A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res 58:329–333PubMedCrossRef Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y (2005) A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res 58:329–333PubMedCrossRef
17.
go back to reference Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y (1998) A PHEX gene mutation is responsible for adult-onset vitamin d-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from x-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 83:3459–3462CrossRef Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y (1998) A PHEX gene mutation is responsible for adult-onset vitamin d-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from x-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 83:3459–3462CrossRef
18.
go back to reference Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, Cowell CT, Carpenter TO (2001) Mutational analysis and genotype-phenotype correlation of the phex gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 86:3889-3899PubMedCrossRef Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, Cowell CT, Carpenter TO (2001) Mutational analysis and genotype-phenotype correlation of the phex gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 86:3889-3899PubMedCrossRef
19.
go back to reference Francis F, Strom TM, Hennig S, Boddrich A, Lorenz B, Brandau O, Mohnike KL, Cagnoli M, Steffens C, Klages S, Borzym K, Pohl T, Oudet C, Econs MJ, Rowe PS, Reinhardt R, Meitinger T, Lehrach H (1997) Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets. Genome Res 7:573–585PubMed Francis F, Strom TM, Hennig S, Boddrich A, Lorenz B, Brandau O, Mohnike KL, Cagnoli M, Steffens C, Klages S, Borzym K, Pohl T, Oudet C, Econs MJ, Rowe PS, Reinhardt R, Meitinger T, Lehrach H (1997) Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets. Genome Res 7:573–585PubMed
20.
go back to reference Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2(7929):309–310PubMedCrossRef Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2(7929):309–310PubMedCrossRef
21.
go back to reference Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055–2061PubMedCrossRef Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055–2061PubMedCrossRef
22.
go back to reference Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S. (2002) Increased circulatory level of biologically active full-length FGF23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960PubMedCrossRef Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S. (2002) Increased circulatory level of biologically active full-length FGF23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960PubMedCrossRef
23.
go back to reference Lo FS, Kuo MT, Wang CJ, Chang CH, Lee ZL, Van YH (2006). Two novel PHEX mutations in Taiwanese patients with X-linked hypophosphatemic rickets. Nephron Physiol 103:157-163CrossRef Lo FS, Kuo MT, Wang CJ, Chang CH, Lee ZL, Van YH (2006). Two novel PHEX mutations in Taiwanese patients with X-linked hypophosphatemic rickets. Nephron Physiol 103:157-163CrossRef
24.
go back to reference Tyynismaa H, Kaitila I, Nanto-Salonen K, Ala-Houhala M, Alitalo T (2000) Identification of fifteen novel PHEX gene mutations in Finnish patients with hypophosphatemic rickets. Hum Mutat 15:383-384PubMedCrossRef Tyynismaa H, Kaitila I, Nanto-Salonen K, Ala-Houhala M, Alitalo T (2000) Identification of fifteen novel PHEX gene mutations in Finnish patients with hypophosphatemic rickets. Hum Mutat 15:383-384PubMedCrossRef
25.
go back to reference Sabbagh Y, Boileau G, DesGroseillers L, Tenenhouse HS (2001) Disease-causing missense mutations in the PHEX gene interfere with membrane targeting of the recombinant protein. Hum Mol Genet 10:1539–1546PubMedCrossRef Sabbagh Y, Boileau G, DesGroseillers L, Tenenhouse HS (2001) Disease-causing missense mutations in the PHEX gene interfere with membrane targeting of the recombinant protein. Hum Mol Genet 10:1539–1546PubMedCrossRef
26.
go back to reference Sabbagh Y, Boileau G, Campos M, Carmona AK, Tenenhouse HS (2003) Structure and function of disease-causing missense mutations in the PHEX gene. J Clin Endocrinol Metab 88:2213-2222PubMedCrossRef Sabbagh Y, Boileau G, Campos M, Carmona AK, Tenenhouse HS (2003) Structure and function of disease-causing missense mutations in the PHEX gene. J Clin Endocrinol Metab 88:2213-2222PubMedCrossRef
27.
go back to reference Tenenhouse HS (1999) X-linked phypophosphataemia: a homologous disorder in humans and mice. Nephrol Dial Transplant 14:333-341PubMedCrossRef Tenenhouse HS (1999) X-linked phypophosphataemia: a homologous disorder in humans and mice. Nephrol Dial Transplant 14:333-341PubMedCrossRef
28.
go back to reference Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500–6505PubMedCrossRef Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500–6505PubMedCrossRef
29.
go back to reference Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB (2004) Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087–3094PubMedCrossRef Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB (2004) Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087–3094PubMedCrossRef
30.
go back to reference Bai X, Miao D, Li J, Goltzman D, Karaplis AC (2004) Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145:5269–5279PubMedCrossRef Bai X, Miao D, Li J, Goltzman D, Karaplis AC (2004) Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145:5269–5279PubMedCrossRef
31.
go back to reference Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto KI, Fukushima N (2003) Human fibroblast growth factor−23 mutants suppress Na-dependent phosphate co-transport activity and 1,25-dihydroxyvitamin D3 production. J Biol Chem 278:2206–2211PubMedCrossRef Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto KI, Fukushima N (2003) Human fibroblast growth factor−23 mutants suppress Na-dependent phosphate co-transport activity and 1,25-dihydroxyvitamin D3 production. J Biol Chem 278:2206–2211PubMedCrossRef
Metadata
Title
Three Novel Mutations of the PHEX Gene in Three Chinese Families with X-linked Dominant Hypophosphatemic Rickets
Authors
Weibo Xia
Xunwu Meng
Yan Jiang
Mei Li
Xiaoping Xing
Li Pang
Ou Wang
Yu Pei
Li-Yun Yu
Yue Sun
Yingying Hu
Xueying Zhou
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 6/2007
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-007-9067-4

Other articles of this Issue 6/2007

Calcified Tissue International 6/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.